Evommune (EVMN) Income from Continuing Operations (2024 - 2026)
Evommune (EVMN) posted quarterly Income from Continuing Operations of 113645000.0 for Q1 2026, down 677.38% year-over-year from 19682920.31 in Q1 2025, and down 302.57% quarter-over-quarter from 28230000.0 in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Income from Continuing Operations for 3 consecutive years, with 113645000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 677.38% year-over-year to 113645000.0; the TTM figure through Mar 2026 stood at 175868000.0 (changed N/A YoY), while the FY2025 annual figure was 132251000.0, down 95.72% from the prior year.
- Income from Continuing Operations retreated to 113645000.0 in Q1 2026 per EVMN's latest filing, from 28230000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 14619000.0 in Q1 2025 and bottomed at 113645000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 35419500.0 across 3 years, with a median of 20053500.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slipped 21.73% — and 2026, when it plunged 677.38%.
- Evommune's Income from Continuing Operations stood at 20733000.0 in 2024, then sank by 36.16% to 28230000.0 in 2025, then plunged by 302.57% to 113645000.0 in 2026.
- Business Quant data shows EVMN's Income from Continuing Operations at 113645000.0 in Q1 2026, 28230000.0 in Q4 2025, and 19374000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Evommune | 445.37 Mn | 244.58 Mn | - | -32.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.25 Mn |
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -28.27 Mn |
| Sep 30, 2025 | -12.48 Mn |
| Jun 30, 2025 | -22.62 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -20.73 Mn |
| Sep 30, 2024 | -15.92 Mn |